Jazz Pharmaceuticals (JAZZ) Stock Price, Quote, News & History | Benzinga

Jazz Pharmaceuticals PLC (JAZZ) Stock Price, Quote, News & History

JAZZNASDAQ

Trade with Public

Trade with Public

$241.39

-2.32-0.95%

Last update: Sep 2, 12:46 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$244.00

Close

-

Volume / Avg.

375.06K / 924.23K

Day Range

$241.02 - $248.07

52 Wk Range

123.88 - 266.38

Market Cap

$15.14B

P/E Ratio

16.69

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

6.63%

Days to Cover

3.81

Recent Jazz Pharmaceuticals PLC News

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.

Avi Kapoor

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut $MSTR target, Barclays raised $MDB target, UBS raised $SMTC target.

Avi Kapoor

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.

Vandana Singh

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

Vandana Singh

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.66B

Investing Cash Flow (TTM)

-221.91M

Financing Cash Flow (TTM)

-1.01B

Free Cash Flow (TTM)

1.31B

Capital Expenditure (TTM)

-349.95M

Net Change in Cash (TTM)

430.68M

Analyst Trends and Forecast

7

1

May

1

Jun

6

Jul

14

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$18.04B

PE Ratio (TTM)

16.69

PE Ratio (FWD)

11.04

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.41

PB Ratio (TTM)

3.30

Earnings Yield % (TTM)

5.99%

Earnings Yield % (FWD)

9.06%

EV / EBITDA (TTM)

11.16

Price / EBITDA (TTM)

9.70

Price / Free Cash Flow (TTM)

11.96

Book Value / Share

$73.97

Company Debt

Total Debt

$4.35B

LT Debt

$3.34B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.03B

Total Cash

$1.62B

Debt to Equity

0.92

Issuance of Debt (TTM)

-$1.03B

Repayment of Debt (TTM)

-$1.03B

Key Statistics

Open

$244.00

Close

-

Volume / Avg.

375.06K / 924.23K

Day Range

$241.02 - $248.07

52 Wk Range

123.88 - 266.38

Market Cap

$15.14B

P/E Ratio

16.69

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

6.63%

Days to Cover

3.81

About

Sector

Health Care

Industry

Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Jazz Pharmaceuticals (JAZZ) stock?

A

You can purchase shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Jazz Pharmaceuticals (JAZZ) competitors?

A

Other companies in Jazz Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Jazz Pharmaceuticals (JAZZ) stock?

A

Jazz Pharmaceuticals has a consensus price target of $256.56.

Q

What is the current price for Jazz Pharmaceuticals (JAZZ)?

A

The stock price for Jazz Pharmaceuticals (NASDAQ: JAZZ) is $241.39 last updated September 2, 2026 at 12:46 PM EDT.

Q

Does Jazz Pharmaceuticals (JAZZ) pay a dividend?

A

There are no upcoming dividends for Jazz Pharmaceuticals.

Q

When is Jazz Pharmaceuticals (NASDAQ:JAZZ) reporting earnings?

A

Jazz Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Jazz Pharmaceuticals (JAZZ) going to split?

A

There is no upcoming split for Jazz Pharmaceuticals.

Q

What sector and industry does Jazz Pharmaceuticals (JAZZ) operate in?

A

Jazz Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.